肝脏疾病中的PARP-1:分子机制,治疗潜力和新兴的临床应用 (综述)
Kaipeng Hu1, Heng Tian2, Shuxing Chen2
1Department of Gastroenterology, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230071, P.R. China.
Molecular medicine reports
|September 26, 2025
概括
在肝病的发展和进展中,PARP-1 (Poly(ADP-ribose) 聚合酶-1 (PARP-1) 是至关重要的. PARP 抑制剂显示为治疗各种肝病的新疗法,包括癌症和脂肪肝疾病.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 肝硬化,HCC和NAFLD等肝脏疾病带来了重大的健康挑战,其临床结果低于最佳.
- 聚ADP-ribose) 聚合酶-1 (PARP-1),一种用于DNA修复的酶,因其在肝脏病理生理学中的作用越来越受认可.
- 了解PARP-1的功能对于开发用于肝脏疾病的新疗法至关重要.
研究的目的:
- 审查PARP-1在各种肝脏疾病中的表达,调节和机制.
- 探索PARP-1在肝脏疾病相关的细胞信号通路中的参与.
- 讨论PARP抑制剂在肝脏疾病管理中的治疗潜力.
主要方法:
- 关于PARP-1在病毒性肝炎,酒精性肝病,NAFLD,纤维化,HCC,药物诱导的肝损伤和自身免疫性肝病中的作用的综合文献综述.
- 分析PARP-1在炎症,亡和免疫调节途径中的参与.
- 对针对PARP-1的现有和新兴治疗策略的评估.
主要成果:
- PARP-1 参与了许多肝脏疾病的发病.
- PARP-1 影响关键的细胞过程,包括炎症,亡和免疫反应.
- PARP 抑制剂显示出作为单独或组合疗法的治疗剂的潜力.
结论:
- PARP-1 是一种临床相关的生物标志物和肝脏疾病的治疗标.
- PARP 抑制剂为改善肝病患者的治疗结果提供了一个有希望的途径.
- 需要进一步的研究来优化基于PARP-1的诊断和治疗,并克服耐药性.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
01:24Liver Regeneration
4.3K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.3K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
215
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
215